Chapter 43: Organic Chemistry Today

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine stepping into a world where we just sort of expect a solution for every illness or a new material for every problem we face.

Just think about the clothes you're wearing or the paint on your walls, maybe, or, well, most dramatically, the medicines that keep us healthy, that save lives.

There's this hidden force really shaping these everyday realities and it's organic chemistry.

It's this ingenious science that has totally transformed our expectations of what's even possible.

Today, we're taking a deep dive into a really fascinating chapter from Organic Chemistry Second Edition by Clayton, Greaves, and Warren.

We want to unpack how this fundamental science is right there at the cutting edge of medical breakthroughs.

Precisely.

And our mission today, really, is to explore how organic chemists, through some incredibly clever thinking,

you know, understanding how molecules react, how to build them precisely with specific 3D shapes, and even working backwards, reverse engineering complex designs, they literally construct the molecules that, well, improve and save lives.

Literally build them.

Yeah, literally.

And you'll see just how deeply chemistry is woven into biology, physics, engineering.

It's a real testament to human ingenuity, working right down at the molecular scale.

It truly is.

Modern science, it really thrives on this kind of interdisciplinary collaboration, doesn't it?

Absolutely.

And organic chemistry has been absolutely central to our ability to understand and manipulate the world at its most fundamental level.

It's almost like we've learned the very language of molecules, and now we can write completely new stories with them.

And nowhere has this transformation been more profound than in medicine, especially through these extraordinary partnerships that really blossomed between organic chemists and biologists, sort of around the turn of the 21st century.

What's so compelling here is that, well, the journey to a new treatment can be long, obviously, but the progress, once you achieve it, it's incredibly robust.

Think about what we often just call the cure for cancer.

It's not one single cure.

It's many diseases.

Exactly.

It's hundreds of successful treatments for the hundreds of distinct diseases we group under that umbrella.

By the early 2000s, there was already a real chance of survival for pretty much all known types of childhood cancer.

That was a huge leap forward.

That's a remarkable success story.

Can you maybe share some specific examples, things that really highlight organic chemistry's role in these revelations?

Absolutely.

Think about Glyvec or Imatinib.

Launched back in 2001,

this drug has effectively revolutionized the treatment for chronic myeloid leukemia.

Well, it essentially cures about 75 % of patients.

Wow, 75%.

Yeah.

Then there's 5 -fluoracil.

That's a much older chemotherapy drug, been around a while, slows cancer progression.

But its effectiveness against certain colon cancers just shoots up dramatically when you combine it with Avastin or Bivacizumab.

Avastin.

What does that do differently?

Avastin is really groundbreaking.

It stops tumors from developing their own blood supply, basically starves them.

Ah, okay.

Cuts off their lifeline.

Pretty much.

And Avastin also significantly boosts the effectiveness of Taxol, you know, Paclitaxel, a powerful breast cancer drug that came out in 92.

So we've got this range, then, from simpler structures like 5 -fluoracil to these really complex things like Avastin.

What's the overarching insight here?

How does organic chemistry tackle such different targets?

Well, these diverse examples really showcase organic chemistry's incredible range, don't they?

Its ability to custom design solutions that specifically hit disease pathways.

So 5 -fluoracil, it's a small molecule,

precisely engineered to mess with cancer cell division.

Taxol, originally found in the Pacific eutri, though now it's made more sustainably through fermentation.

Right.

Its power lies in its unique molecular structure, its scaffold.

Then you have Avastin, which is totally different, it's a huge antibody, a protein.

It's produced by actually modifying gene expression in bacteria.

So completely different ways of making them, too.

Completely.

But the insight is that whether it's a small synthetic compound or a massive biologically produced molecule, the fundamental understanding of molecular structure, how things interact,

that's rooted in organic chemistry.

That's what enables these treatments.

It's really molecular engineering at its finest.

And trying to draw some sharp line, you know, this is chemistry, this is biology, this is medicine.

It's often kind of pointless.

They're just deeply, beautifully integrated.

That integration, it really shines through when we look at another critical battleground,

the fight against viruses.

Let's talk about the AIDS crisis in the 1980s.

I mean, biologists quickly identified HIV as the cause, right?

Relatively quickly, yeah.

And those early antiviral drugs like AZT, they offered some initial hope.

They basically mimicked natural building blocks, didn't they, to sort of trick the virus.

That's right.

They inhibited its ability to copy its genetic material inside human cells using an enzyme called reverse transcriptase.

But the really significant challenge with those early drugs, much like some early anti -cancer drugs,

was toxicity.

Right, the side effects.

Exactly.

They weren't selective enough.

They ended up inhibiting essential human enzymes too, not just the viral ones.

This is where a truly critical turning point came.

Biologists discovered an enzyme that was unique to the virus, HIV protease.

Ah, something only the virus had.

Precisely.

This enzyme is absolutely essential for the virus to mature and replicate.

So the crucial insight was, if we can block this specific viral enzyme.

Then you stop the virus without harming the patient's cells.

Exactly.

New viruses wouldn't form, and crucially, the inhibitor wouldn't mess with human biochemistry.

It was, well, an ideal therapeutic target.

That sounds like a brilliant target.

Yeah.

Okay, so how did chemists then design drugs to block only this unique viral protease?

Well, the chemical solution for these HIV protease inhibitors was incredibly clever.

The drugs were designed to look like the proteins the enzyme would normally cut, but with a key difference.

They were chemically stable.

They couldn't actually be broken down or hydrolyzed by the enzyme.

So they get stuck in the enzyme.

Essentially, yeah.

They jam it.

It's like they engineered an uncuttable key that permanently jams the lock, just like you said earlier.

Wow.

Chemists use their deep understanding of enzyme mechanisms.

Enzymes bind to this fleeting, unstable structure that forms during a reaction, we call it a transition state.

Right.

That high energy point.

Exactly.

Now, you can't really make a stable molecule that is a transition state.

They're too unstable.

But you can design a molecule that closely resembles a stable intermediate in the cutting process.

This mimic was so convincing that the protease would bind it really tightly in its active site.

Thinking it's the real thing.

Thinking it's the real thing.

But because the drug couldn't actually be processed, it just stayed put, blocked the enzyme's function entirely.

And this design wasn't guesswork.

It was guided by detailed structural information, like x -ray crystal structures.

Seeing the actual shape.

Seeing the shape of the enzyme's active site.

This allowed chemists to precisely sculpt compounds like ritonavir and indivir to fit perfectly.

And the impact of this work was just monumental, wasn't it?

In the 90s, this combination therapy, using indivir with other antivirals,

it changed everything for HIV treatment.

It completely revolutionized it.

Before this, like you said, many people with HIV faced maybe only two years.

Now, with these combination therapies, the virus can often be reduced to undetectable It transformed HIV from, well, a death sentence into a manageable chronic condition.

Absolutely.

And this breakthrough, it really stands as an unparalleled example of cooperation.

The AIDS crisis spurred this extraordinary collaboration.

Pharma companies, government agencies, universities, all working together.

They had to, didn't they?

They had to.

And once indivir was found to be effective, the urgency for the chemists was just immense.

They knew roughly a kilogram of the compound was needed to keep each patient alive for a year.

A kilogram per patient per year.

That's a lot of drug to make.

It's a huge amount.

Merck responded incredibly fast.

They built a dedicated plant just for indivir manufacture in 1995.

Within a year, production was at full capacity, and it's estimated that millions of people are alive today as a direct result of this chemical synthesis effort.

OK, let's unpack this indivir molecule a bit more then.

You said it was incredibly complex.

Can you give us a sense of the chemical puzzle involved in actually making it on that kind of scale?

Oh, indivir was, and still is, a really formidable synthetic target.

It was probably the most complex compound ever made in that kind of quantity by organic synthesis back then.

What made it so complex?

The sheer complexity mostly came from its precise 3D architecture.

It has to be a single enantiomer.

Meaning just one specific mirror image form works?

Exactly.

The only one spatial arrangement of its atoms is effective, and it has five stereogenic centers, those specific points in the molecule that define its unique 3D shape.

So making that required devising three separate sections of asymmetric synthesis controlling that 3D shape, which is a massive challenge to do with high precision and efficiency, especially on scale.

And how did they even start to approach building something that intricate?

You don't just toss things in a flask and hope for the best?

Definitely not.

They used what we call retrosynthetic analysis.

It's a really powerful strategy in organic chemistry.

You essentially work backward from your target molecule.

Like planning a route by starting at the destination.

Kind of, yeah.

You break it down into smaller, simpler pieces, like reverse engineering a complex machine.

For indivir, it was disconnected into five manageable fragments.

And three of these fragments contained those crucial stereogenic centers, so they had to be made as single enantiomers, guaranteeing their precise 3D form right from the start.

So breaking it down into smaller chiral pieces, what were some of the, I guess, clever strategies for making those specific chiral fragments?

I'm really curious about the ingenuity here.

Right.

Well, several different asymmetric methods were key.

For the central epoxide fragment, they used the Sharpless asymmetric epoxidation.

It's a Nobel Prize winning reaction, brilliant for making epoxides as single enantiomers.

For another piece, the piperazine fragment, they use enantioselective hydrogenation.

This uses special catalysts, like those with binaplagans, to add hydrogen in a very specific way, creating the desired stereocenter.

Much better than older, less efficient methods.

And the third chiral piece?

That was the aminoindanol fragment.

Its synthesis involved a few steps starting from indine, including another epoxidation, but this time they used a different method, the Jacobson epoxidation, or sometimes an older method involving resolution separating a mess of mirror images.

So different tools for different parts.

Wow, a whole toolkit of asymmetric reactions.

Exactly.

But maybe the most remarkable reaction in the whole synthesis was how they formed the final stereogenic center.

Usually, to make sure a new bond forms with a specific 3D shape, chemists might attach a temporary helper molecule, a chiral auxiliary, to guide the reaction.

Then you have to remove it later, which adds steps and waste.

Okay.

But the Merck chemist made this incredible discovery.

A part of the indinevir precursor molecule itself, this amino alcohol bit, actually acted as its own chiral auxiliary.

The molecule directed itself.

Essentially, yes.

It guided the formation of that last stereogenic center with amazing precision.

It was similar in concept to how Evans auxiliaries work, but using part of the molecule itself.

This completely eliminated the need for adding and removing a separate auxiliary.

It saved steps, reduced waste.

Just a beautiful piece of chemical elegance.

That is fascinating.

Bringing the molecule sort of, yeah, self -directing its own construction.

So efficient.

And then bringing all these carefully crafted pieces together at the end.

The final assembly involved strategically connecting these fragments.

They used key reactions like imanum alkylations, forming bonds between nitrogen and carbon, and then some careful deprotection steps, removing temporary blocking groups.

It really is a masterclass in multi -step organic synthesis, bringing all those fragments together, like assembling a very complex 3D puzzle to finally form indivir.

Incredible stuff.

Okay, let's shift gears slightly.

From one critical battle, HIV, to another major public health threat,

influenza, the flu.

We've seen past pandemics claim millions of lives, and virologists are always warning us, right, that a global flu pandemic remains a constant danger.

It's always a possibility.

And here, organic chemists have given us oseltamivir, which most people know as tomiflu.

This is a neuraminidase inhibitor.

How does that work, basically?

So the neuraminidase enzyme is what the flu virus uses to cut itself free from an infected host cell, so it can go off and infect more cells.

Oseltamivir blocks that enzyme, it gums up the work so the newly formed viruses can't escape.

They're trapped, effectively stopping the spread of the infection within the body.

Okay, stops it in its tracks.

Yeah.

Now, the story of making tomiflu is also interesting, especially the starting materials, isn't it?

Very interesting, yes, particularly the supply chain challenges.

The initial manufacturing route relied on a natural product, techa -aquinic acid.

You find that in coffee beans.

Coffee beans, really?

Yeah.

But the problem was, the amount you could get globally just wasn't enough for widespread use, especially if a pandemic hit, it created a critical bottleneck.

So that led to a switch to a different natural starting material,

shikimic acid.

Shikimic acid, where does that come from?

It's a plant metabolite, and it's abundant in the spice star anise.

You know, the star shape spice used in cooking.

Ah.

Okay.

So even starting with shikimic acid, which I guess shares some structural features with tomiflu, it still required a lot of chemical innovation to turn it into the actual drug.

Oh, absolutely.

The original route from shikimic acid was, well, complex.

It involved many steps.

Especially tricky was introducing the two amino groups with the precise 3D orientation, the stereochemistry that tomiflu needs.

A winding path, you said?

It was a bit of a winding path, yeah, but it worked.

For instance, they used this clever sequence involving an aziridine intermediate.

Think of it as a small, strained, three -membered ring containing nitrogen.

Okay.

They could then open that ring in a highly controlled way, using azide, to place one of the amino groups exactly where it needed to be.

It also involved steps like the Stardinger reaction to convert the azide to the amine.

Sounds incredibly intricate, but maybe also, like, it might have some challenges on an

Using azides, for instance, can be risky.

It did have challenges.

Azides can be potentially explosive, which requires careful handling on a large scale.

And the route wasn't the most efficient overall.

Lots of steps.

Generated quite a bit of waste.

But despite that, for several years, it was the best way they had.

And Roche successfully scaled it up for commercial production, which was a huge chemical engineering achievement in itself.

Now this next part of the story, this is where it gets really interesting, I think.

In 2006, the Nobel Prize -winning chemist E .J.

Corey published a totally different way to make oseltamivir.

Yes, a landmark synthesis.

How did his approach differ?

What made it so remarkable?

Well, Corey's route completely bypassed the reliance on natural starting materials like shakimic acid.

Instead, it leveraged the power and efficiency of the Diels -Alder reaction.

Okay, a fundamental reaction for building rings.

Exactly.

Instead of starting with a complex natural product that already has some structure you need to modify, sometimes extensively,

Corey's team began with very cheap, simple, readily available reagents like butadiene and an acrylate derivative.

And crucially, they used a tiny amount of a chiral catalyst, a special molecule that directs the reaction to make that very first ring -forming step happen enantioselectively.

So getting the 3D shape right from the very beginning.

Right from the outset.

It elegantly set the stage for the rest of the synthesis.

It completely avoided the supply issues of starbanese and the need for lots of steps just to correct the structure later on.

A much cleaner, more efficient start, it sounds like.

What were some of the key ideas in Corey's route then to build out the rest of the molecule?

From that initial Diels -Alder product, which now had the correct core shape, the existing 3D information was cleverly used to control the creation of the other chiral centers.

One key step was something called iodo -lactamization.

It's an intramolecular reaction.

Part of the molecule loops back on itself to create a specific bond and set a precise 3D arrangement.

Using the molecule's own shape to guide itself again.

Exactly.

Then subsequent steps strategically added the second nitrogen group, again using aziridine chemistry but in a different way, and finally introduced that crucial ether group.

So how did Corey's route stack up?

Was it much more efficient than the original shechemic acid route?

It was a significant improvement, yes.

Fewer steps overall and a much better overall yield, something like 30 % yield over 12 steps, which was quite good for this complexity.

Now it still presented some challenges for industrial scale up, some of the reaction conditions were a bit tricky, but it represented a major leap forward in synthetic efficiency and design, and chemists are still exploring even shorter, greener routes today.

Which leads us nicely to a broader perspective, doesn't it?

Because not all organic chemists are directly working on making Tamiflu or Indonevir, but their fundamental research, sometimes stuff that seems really obscure, is absolutely crucial.

Absolutely crucial.

It really illustrates the unpredictable nature of scientific discovery, and it's a powerful reminder that fundamental curiosity -driven research, even if it seems niche at the time, it lays the essential groundwork for tomorrow's breakthroughs, things we can't even foresee.

Can you give an example of that?

Sure.

Consider Giovanni Casiraghi's work back in 1980.

He published this, well, fairly modest paper on some specific reactions of phenols and formaldehyde, seems quite specific, right?

But that foundational work later proved absolutely crucial for developing Jacobson's asymmetric epoxidation catalysts.

Which you mentioned was using the Indonevir synthesis.

Exactly.

A cornerstone method used to make one of those key chiral fragments.

Without Casiraghi's earlier, seemingly unrelated work, Jacobson might not have developed his catalyst in the same way.

Wow.

It's incredible how these threads connect over decades.

It really makes you think about the importance of funding basic science, doesn't it?

Things that might not have an immediate, obvious payoff.

It really does.

Or think about even older discoveries, like the Duff reaction from the 1930s.

Again, reactions dealing with adding carbon atoms to phenols.

Might have seemed quite academic back then.

Yet modifications of these methods, building on that fundamental understanding, became vital tools.

It shows how these fundamental discoveries, often made without any clue about their future application, become indispensable.

It's truly impossible, even for the inventor sometimes, to predict the ultimate importance of a discovery.

The lesson is just the immense value of supporting basic scientific inquiry across the board.

So thinking about that, what does this all mean for you, our listeners, as we look to the future of organic chemistry?

What's on the horizon?

Well, the field is just constantly evolving at an astounding pace, really.

We're seeing advances in reactions that would have seemed, well, almost like science fiction just a decade or two ago.

For example, there's this really exciting concept of chiral anion catalysis.

Chiral anions.

Negatively charged molecules controlling shape.

Exactly.

It's a groundbreaking new approach, where even these fleeting, negatively charged ions can influence the 3D shape of the final product.

It offers potentially unprecedented control over how molecules are built.

We're also seeing the rise of something called diversity -oriented synthesis.

Diversity -oriented.

What's the idea there?

The idea isn't necessarily to make one specific drug target right now.

It's about developing methods to quickly make huge numbers, vast families, of complex and diverse molecules, many of which have never existed before.

The hope is that within these massive libraries of new structures, we'll find completely novel starting points for attacking diseases in new ways, or discovering materials with unique properties.

It's like building a giant molecular toolkit for future, maybe even unknown challenges.

It's almost like giving ourselves a whole new, much bigger box of Lego bricks, isn't it?

And then just letting chemists build and discover what's possible.

That's a great analogy, yeah.

It makes me think about, you know, nature's incredible synthetic ability versus what chemists can do.

Well, nature is, without a doubt, a superb synthetic chemist.

It's evolved these incredibly efficient pathways over millions of years,

but nature operates within certain constraints, right?

Molecules can only be biosynthesized if the enzymes to make them exist, and those enzymes are built from a fairly limited set of amino acid building blocks.

Chemists, on the other hand, we have the entire periodic table to play with.

We have raw materials, labs, and, well, boundless ingenuity.

We can, in principle, make anything.

We can sometimes even tweak nature's enzymes, evolve them in the lab to do new tricks.

But more often, chemists use reactions and reagents that nature simply can't.

Things involving organometallic catalysts using metals like rhodium, palladium, ruthenium, or complex phosphorus ligands, things that just don't exist in biology.

Which means the possibilities are just limitless, really.

And the next big breakthrough could come from anywhere.

Precisely.

The molecules chemists will make in the future, and maybe even more importantly, how they make them more efficiently, more sustainably, that will determine the well -being of huge numbers of people, often in ways that are completely impossible for us to predict today.

That's the profound, ongoing power and impact of organic chemistry.

And there you have it.

You've just gotten a deep dive into how molecules are built, often with just incredible precision and creativity.

It really showcases the immense power of fundamental understanding in organic chemistry.

It's a field that's constantly pushing boundaries and, well, literally shaping the world around us, often in ways we don't even realize day to day.

And your journey into understanding this molecular world, it's truly just beginning.

This deep dive, hopefully, has equipped you with a glimpse into organic chemistry's fundamental knowledge and its really transformative power.

The future of global health, of technological innovation, of solving some of the world's most pressing challenges.

It rests on continued exploration and discovery in this incredibly dynamic field.

There's always more to learn, and who knows?

The next breakthrough could very well be yours to discover, or perhaps to utilize in ways we haven't even thought of yet.